Newsletter | February 10, 2023

02.10.23 -- Solve Clinical Trial Consulting & Regulatory Challenges With Key Partners

 
     
 
 
 
     
 
     
 
How A Top Pharma Increased Regulatory Speed And Consistency With Business Process Automation
 

Discover how PhlexRIM’s preconfigured business process automation helped the company rapidly build streamlined regulatory workflows and lifecycles aligned with their internal processes – increasing the efficiency and consistency of regulatory operations.

 
 
 
 
 
 
     
 
The Composition And Value Of A Portfolio Analysis
 

One of Premier Consulting’s differentiating offerings is the portfolio analysis: a high-level, integrated evaluation of the scientific, medical, regulatory, and commercial viability of each product within a sponsor’s portfolio.

 
 
 
 
 
 
     
 
Centralize Your Labeling Workflow Management
 

TransPerfect Life Sciences supports clinical supply teams with an end-to-end labeling process that ensures compliance and reduces timelines to speed up regulatory approvals.

 
 
 
 
 
 
     
 
Marketing Applications For Regulatory Approval
 

Preparing regulatory marketing applications to their successful conclusions is our focus.

 
 
 
 
 
 
     
 
eClinical Consulting
 

Explore what YPrime's eClinical consultants can provide for life science customers, from trusted advice to expert support.

 
 
 
 
 
 
     
 
How To Ensure Local-Level Pharmacovigilance Compliance And Efficiency
 

Beyond meeting compliance standards, pharmaceutical companies must implement the quality systems necessary to handle data in the local language, ensure data privacy, and minimize risk.

 
 
 
 
 
 
     
 
NDA-Enabling Studies
 

For over 25 years, we have been designing and running a broad range of early phase studies required for NDA submissions. We are experts in the design and conduct of early clinical development plans and stand-alone studies.

 
 
 
 
 
 
     
 
Supporting Enrollment Of A Phase 2 Cervical Cancer Study During A Pandemic
 

The developer of an investigative medicinal product (IMP) for advanced, recurrent, non-resectable cervical cancer engaged Premier Research to assist with screening and enrollment in a Phase 2 study in Europe. Find out the results of this partnership.

 
 
 
 
 
 
     
 
New Is Risky. Start With A Free Feasibility Report.
 

Get a free preliminary evaluation of your protocol design from a leading CRO in Eastern Europe.

 
 
 
 
 
 
     
 
Development And Regulatory Strategy For US And China
 

This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.